FLIPI24
FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.
Author / Source: Contributed by Dr. Matthew J Maurer and created by QxMD
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
- [1]MJ Maurer et al, : FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.ASH Annual Meeting 2022, Abstract 953
Results
Real-time automated computation
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
- [1]MJ Maurer et al, : FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.ASH Annual Meeting 2022, Abstract 953